Randomized, Double-blind, Multi-centre, Parallel-goup Study to Investigate the Efficacy and Safety of Three Doses of BAY38-9456 (5 mg, 10 mg and 20 mg) Versus Placebo in the Treatment of Patients With Erectile Dysfunction

NCT00668057 Phase 3 COMPLETED

This study was to compare the efficacy of 3 doses of vardenafil, 5 mg, 10 mg and 20 mg, with matching placebo in Chinese male ED patients, treated for a maximum of 12 weeks.

Details

Lead sponsor	Bayer
Phase	Phase 3
Status	COMPLETED
Enrolment	624
Start date	2002-12
Completion	2003-09

Conditions

• Erectile Dysfunction

Interventions

• Levitra (Vardenafil, BAY38-9456)
• Levitra (Vardenafil, BAY38-9456)
• Levitra (Vardenafil, BAY38-9456)
• Placebo
• Placebo
• Placebo

Primary outcomes

• Erectile Function domain score of the International Index of Erectile Function, questions 1-5 and 15 — 12 weeks

Countries

China